Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting

Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting

Background: Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy. Methods: We retrospectively assessed the incidence of AEs of special interest and managem...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibraheem Othman, Seyedeh Zahra (Mona) Moossavi, Samaneh Bayati, Yi Sin Chang, Shubrandu Sanjoy, Karolina Grzyb, Eric Sy, Kayla Cropper, Sandy Kassir, Waleed Sabry
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Current Oncology
Subjects:
chronic lymphocytic leukemia
ibrutinib
adverse events
treatment discontinuation
Online Access:https://www.mdpi.com/1718-7729/32/6/296
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/6/296

Similar Items